Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115322 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
A Phase 1 study of Acne Vulgaris, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01115322 is a Phase 1 study of Acne Vulgaris that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 38 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01115322, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.
Conditions Studied
Interventions
- DRUG Tazarotene Foam without irradiation
- DRUG Tazarotene Foam with UVA and UVB irradiation
- DRUG Tazarotene Foam with UVA, UVB, and visible light
- DRUG Vehicle Foam without irradiation
- DRUG Vehicle Foam with UVA and UVB irradiation
Study Locations (1)
Arizona
- HillTop Research Corporation - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04-01 |
| Est. Completion | 2010-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01115322
The ClinicalTrials.gov registry entry for NCT01115322 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (86% lower). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 5 interventions - of which Tazarotene Foam without irradiation is the first listed.
NCT01115322 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01115322 about?
NCT01115322 is a clinical study titled "A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers". The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.
What is the current status of trial NCT01115322?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2010-04-01. Estimated completion is 2010-04-10.
What conditions does trial NCT01115322 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01115322?
The interventions under investigation include: Tazarotene Foam without irradiation (DRUG), Tazarotene Foam with UVA and UVB irradiation (DRUG), Tazarotene Foam with UVA, UVB, and visible light (DRUG), Vehicle Foam without irradiation (DRUG), Vehicle Foam with UVA and UVB irradiation (DRUG).
Who is sponsoring clinical trial NCT01115322?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115322 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
COMPLETED · Phase 1
-
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.